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Purpose: Adhesion and migration of dislocated retinal pigment epithelial (RPE) cells are initial steps in the pathogenesis
of proliferative vitreoretinopathy (PVR). The role of the endogenous lectin, galectin-1, in attachment, spreading, and
migration of human RPE cells was investigated from a therapeutic perspective.
Methods: Human RPE cells were treated with galectin-1 concentrations that ranged 0–250 µg/ml. Cell viability was tested
by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT) assay. Galectin-1 binding to the RPE cells was
investigated by immunocytochemistry. Attachment of RPE cells was assessed on 96-well plates coated with laminin, or
fibronectin, or galectin-1, or the glycoprotein-lectin combinations and subsequent MTT-testing. RPE migration in the
absence or presence of galectin-1 on the respective substrates was tested using a modified Boyden chamber assay with
platelet derived growth factor (PDGF)-BB as the chemoattractant. Cellular spreading was characterized by cytoplasmic
halo formation of RPE cells after three hours in contact with the surface coating.
Results: Galectin-1 bound to the cell surface. Binding could be inhibited by a β-galactoside. MTT assays revealed no
toxicity within control limits for the concentration range tested. When added to the medium, galectin-1 dose-dependently
inhibited RPE cell attachment, spreading, and migration by more than 70%, irrespective of the substratum tested. When
coated onto the plastic surface, galectin-1 alone impaired spreading and migration of RPE cells, and reduced attachment
to and migration on fibronectin by up to 80%.
Conclusions: Galectin-1 inhibits RPE cell attachment, migration, and spreading in vitro with no apparent cytotoxicity.
This activity of the endogenous effector deserves consideration as a potential therapeutic agent for the prevention of PVR.
Despite  continued  advances  in  surgical  techniques,
proliferative vitreoretinopathy (PVR) remains a major cause
of persistent reduction in visual acuity after retinal detachment
or severe ocular trauma [1]. Clinically, PVR is characterized
by the dispersion of a variety of cells into the vitreous and
subsequent formation of scar-like fibrocellular membranes on
the surfaces of the neuroretina, which gives rise to subsequent
tractional retinal detachment or re-detachment [2,3].
PVR membranes typically contain a predominance of
retinal pigment epithelial (RPE) cells. Thus, it is assumed that
the development of PVR critically depends on the capacity of
these cells for proliferation, migration, and matrix remodeling
[4]. Following a retinal injury, RPE cells, which normally
form  a  monolayer  of  polarized,  highly  specialized
nonproliferating cells at Bruch’s membrane, disseminate and
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attach to multiple loci on the neuroretina and the vitreous.
There, they undergo a pseudometaplastic transformation into
fibroblast-like  cells,  which  then  spread  along  the  retinal
surface, actively dividing and migrating. These processes are
suggested to be the key cellular events in the onset of PVR
[2,3,5-7].
Blocking these early cellular responses could be viewed
as a potential therapeutic target for improving the overall
prognosis of surgical treatment. In the past, pharmacologic
prevention  of  PVR  membrane  formation  has  been  based
chiefly  on  anti-proliferative  and  anti-inflammatory  agents
[8-12]. However, the results from these approaches have been
disappointing, largely because of their ineffectiveness or their
ensuing  retinal  toxicity  [8,13].  As  a  consequence,  no
pharmacological adjuvant has yet been established as part of
a routine treatment for PVR, and a need remains for nontoxic
agents that will specifically block cellular activities such as
RPE proliferation and attachment in PVR. One promising
approach would involve the use of endogenous effectors that
normally exert control over cell movement and proliferation.
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2162Our report focuses a protein that is known to regulate cell
adhesion, attachment, migration, and proliferation.
Accumulating evidence reveals the role of cell surface
glycans  as  versatile  biochemical  signals  that  operate  via
translation of sugar-encoded information by carbohydrate-
binding proteins (lectins) [14]. The range of lectin-protein
recognition  processes  in  situ  covers  an  extensive  activity
profile [14,15]. In this respect, the galectin family figures
prominently, due to their multifunctionality. These proteins
are  characterized  functionally  by  their  affinity  for  β-
galactosides and structurally by their β-sandwich fold with a
central Trp residue [16,17].
Because  they  are  often  positioned  at  branch  ends  of
glycan chains, β-galactosides or derivatives thereof represent
ideal  docking  sites  for  galectins  [18,19].  Of  the  many
members of the galectin family, galectin-1 is perhaps the best
characterized, and is found expressed intracellularly, on the
cell surface, and also within the extracellular matrix [20,21].
When  externalized,  galectin-1  participates  in  cell-cell  and
cell-matrix  interactions  through  binding  with  distinct
glycoconjugates present on the cell surface as well as in the
extracellular  matrix  (ECM).  These  glycoconjugates  may
include neutral glycolipids and ganglioside GM1 [22,23], the
α1/α5/α7/β1-integrin subunits in a cell-type specific manner
[24], laminin (Lam) [25], fibronectin (Fn) [26], or suitably
glycosylated  mucin  or  chondroitin  sulfate  proteoglycan
chains, as well as several immune cell CD markers. Many of
these listed components have been shown to be present in PVR
membranes [27].
Depending on the counter-receptor and its glycosylation,
galectin-1  can  differentially  affect  a  variety  of  cellular
functions, including cell proliferation [24,28,29], adhesion
and  migration  [24,30,31],  apoptosis  in  activated  T
lymphocytes [21,32], and induction of anoikis in pancreatic
carcinoma cells [33]. However, it must be noted that these
effects are highly cell type-specific and therefore the response
to galectin-1 binding may vary with the cell type under study.
Most of the cell-adhesion molecules and ECM proteins
that favor the adhesion and migration of RPE cells contain
substantial  numbers  of  β-galactosyl  residues,  which  are
ligands  for  lectins  in  general  and  galectins  in  particular.
Previous work with the agglutinin from the edible mushroom
Agaricus bisporus has revealed substantial inhibition of RPE
migration and proliferation [11,34,35]. We have previously
demonstrated the presence of galectin-1 in PVR membranes
and also have shown that human RPE cells produce galectin-1
both in vivo and in vitro [36]. Galectin-1 has been implicated
in the regulation of cell adhesion, migration, and cell growth
in a wide variety of cell types, including activated T cells,
vascular  smooth  muscle,  neuroblastoma,  and  pancreatic
carcinoma cells [24,29,32,33].
It  was  therefore  of  interest  to  further  investigate  the
potential  role  of  extracellular  galectin-1  in  the  in  vitro
behavior of RPE cells. Treatment with an endogenous lectin,
such as galectin-1, may disclose a new perspective for re-
programming  key  cellular  PVR-related  events,  using  an
endogenous substance synthesized by RPE cells themselves.
Our report is a first step toward establishing the validity of this
hypothesis.
METHODS
Galectin-1  purification,  labeling,  and  quality  controls:
Galectin-1  was  purified  after  recombinant  production  by
affinity  chromatography  on  lactosylated  Sepharose  4B  as
critical step and elution with 100 mM lactose in PBS (20 mM
KH2PO4/Na2HPO4,  150  mM  NaCl,  pH  7.2)  followed  by
dialysis against the same buffer without lactose. The purity of
the final product was checked by gel electrophoresis on a 15%
polyacrylamide  running  gel  and  mass  spectrometry  on  a
YTOF  instrument  type  Q-Tof2  (Waters  Micromass,
Manchester,  UK),  as  described  previously  [30,37].
Biotinylation  was  performed  under  optimized  activity-
preserving  conditions  with  biotinyl-N-hydroxysuccinimide
ester (0.5 mg/mg of protein; Sigma, Deisenhofen, Germany),
predissolved  in  dimethylformamide,  in  carbonate  reaction
buffer (0.1 M NaHCO3; pH 8; 0.9% NaCl, 20 mM lactose).
The degrees of labeling and carbohydrate-binding activity
were measured by two-dimensional gel electrophoresis and
solid-phase and cell assays, as previously described [38,39].
In detail, two-dimensional gel electrophoresis was performed
using  an  Amersham  Biosciences  IPGphorTM  isoelectric
focusing  (IEF)  unit  (Freiburg,  Germany)  for  the  first
dimension followed by separation on 12.5% polyacrylamide
running gels for the second dimension using an Amersham
Biosciences Hoefer SEM 600 model (Freiburg, Germany).
Gels  were  stained  by  application  of  reagents  of  a  silver
staining  kit  (Amersham  Biosciences)  and  were  processed
using an ImageScanner (Amersham Biosciences). For solid-
phase assays, the surface of microtiter plate wells (Greiner
Bio-One, Frickenhausen) was coated with 50 µl PBS (20 mM,
pH 7.2) containing the lectin-reactive glycoprotein (0.5µg
asialofetuin obtained by desialylation of commercial fetuin;
Sigma) at 4 °C overnight. Following blocking residual sites
for protein adsorption by an incubation with 100 µl buffer
containing 1% (w/v) carbohydrate-free BSA (Sigma) for 1 h
at 37 °C and washing, 50 µl of solution containing biotinylated
galectin-1 was applied at a concentration resulting in signal
intensity within the linear range, specifically bound galectin-1
was detected by its biotin label using streptavidin-peroxidase
conjugate  (0.5  µg/ml  for  1  h  at  37  °C;  Sigma)  and  the
chromogenic  substrates  o-phenylenediamine  (1  mg/ml;
Sigma)/ H2O2 (1 µl/ml) at 490 nm with a microplate reader
(Bio-Rad,  Munich,  Germany).  For  cell  surface  binding,
suspensions  with  4×105  cells  per  sample  were  carefully
washed  to  remove  any  interfering  serum  compounds,  the
extent  of  protein  binding  by  nonspecific  interaction  was
reduced  by  an  incubation  step  in  Dulbecco's  phosphate-
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NaCl, and 2.7 mM KCl at pH 7.4) containing 100 µg/ml of
carbohydrate-free BSA, and the biotinylated galectin-1 was
incubated  with  the  cells  for  30  min  at  4  °C  to  minimize
endocytic  uptake.  Quantitative  determination  of
carbohydrate-dependent  galectin-1  binding  using
streptavidin/R-phycoerythrin (1:40) as a fluorescent marker
(Sigma)  was  performed  by  flow  cytofluorometry  in  a
FACScan  instrument  (Becton-Dickinson,  Heidelberg,
Germany).
Isolation of human RPE cells and human RPE cell culture:
Eyes from five human donors (three male, two female) were
obtained from the Munich University Hospital Eye Bank and
were processed within 4–16 h after death. Donors ranged from
22 to 59 years of age. None of the donors had a known history
of  eye  disease.  Methods  for  securing  human  tissue  were
humane, included proper consent and approval, complied with
the Declaration of Helsinki, and were approved by the local
ethics committee. Human RPE cells were harvested following
the procedures described previously [40,41].
In brief, whole eyes were thoroughly cleansed in 0.9%
NaCl solution, immersed in 5% poly(1-vinyl-2-pyrrolidone)-
iodine  (Jodobac,  Bode-Chemie,  Hamburg,  Germany),  and
rinsed again in the sodium-chloride solution. The anterior
segment from each donor eye was removed and the posterior
poles  were  examined  with  the  aid  of  a  binocular
stereomicroscope  to  confirm  the  absence  of  gross  retinal
disease. Next, the neural retinas were carefully peeled away
from the RPE-choroid-sclera using fine forceps. The eye cup
was rinsed with Ca2+ and Mg2+ -free Hank’s balanced salt
solution,  and  filled  with  0.25%  trypsin  (GibcoBRL,
Karlsruhe, Germany) for 4 min at 37 °C. The trypsin was
carefully aspirated and replaced with Dulbecco’s modified
Eagles  medium  (DMEM,  Biochrom,  Berlin,  Germany)
supplemented with 20% fetal calf serum (FCS, Biochrom).
Using a pipette, the media was gently agitated, releasing the
RPE  into  the  media  by  avoiding  damage  to  Bruch’s
membrane. The RPE cell suspension was transferred to a 6-
well  plate  containing  2  ml  of  DMEM  (Biochrom)
supplemented with 20% FCS (Biochrom), checked for cross
contamination using a microscope and maintained at 37 °C
and 5% CO2. After reaching confluency, primary RPE cells
were  subcultured  and  maintained  in  DMEM  (Biochrom)
supplemented with 10% FCS (Biochrom) at 37 °C and 5%
CO2.  Epithelial  origin  was  confirmed  by
immunohistochemical staining for cytokeratin using a pan-
cytokeratin antibody (Sigma). The cells were tested and found
free of contaminating macrophages (anti-CD11; Sigma) and
endothelial cells (anti-von Willbrand factor, Sigma; data not
shown).
Primary RPE cells were subcultured and maintained in
Dulbecco’s modified Eagles medium (DMEM; Biochrom,
Berlin, Germany) supplemented with 10% fetal calf serum
(FCS; Biochrom) at 37 °C and 5% CO2. RPE cells of passages
3–7 were used for experiments. When indicated, different
concentrations  of  galectin-1  were  included  in  the  culture
medium.  The  tetrazolium  dye-reduction  assay,  3-[4,5-
dimethylthiazol-2-yl]-2,5–126  diphenyltetrazoliumbromide
(MTT; Sigma-Aldrich), was used to test for cell viability
[36]. For MTT-testing RPE cells were grown on 96 well
plates. After the respective incubation times with or without
galectin-1 in the medium cells were rinsed with PBS, and
150 µl of MTT working solution (1.5 ml MTT stock, 2 mg/ml
in PBS, plus 28.5 ml DMEM) was added and incubation was
continued at 37 °C for 20 min. Within this incubation period
cells were repeatedly monitored by light microscopy to assure
that the blue formazan crystals did not form outside of the cell.
The formazan crystals were then dissolved by the addition of
dimethyl  sulfoxide  (DMSO,  70  µl/well).  Absorption  was
measured by a scanning multiwell spectrophotometer at 550
nm (Molecular Probes, Garching, Germany). Results were
expressed as the mean percentage of untreated control cells.
Immunocytochemical galectin-1 localization: RPE cells were
seeded on glass coverslips at a density of 2×104 cells per well
and grown for 16 h. Cells were washed three times (three
minutes  each  wash)  in  0.1%  BSA  (BSA)  and  phosphate
buffered saline (PBS; 137 mM NaCl; 2.7 mM KCl, 10 mM
Na2HPO4;  2  mM  KH2PO4;  pH  7.4)  at  room  temperature.
Thereafter  cells  were  treated  with  20  μg/ml  biotinylated
galectin-1 added to DMEM/0.4% FCS for 35 min at 37 °C.
After two washes in PBS, nuclei were counterstained with
1  µg/ml  Hoechst  33342  (Sigma),  followed  by  a  10  min
incubation  at  room  temperature.  Following  another  two
washes in PBS (5 min each wash) at RT, cells were fixed in
2%  paraformaldehyde,  stained  with  Alexa-Fluor  488™-
labeled streptavidin (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions, and mounted in Kaiser gelatin
(Merck, Darmstadt, Germany). Galectin-1-dependent signals
were monitored by fluorescence microscopy (Leica, Wetzlar,
Germany).
Cell  adhesion  assay:  Surfaces  of  96-well  plates  (Nunc,
Wiesbaden,  Germany)  were  coated  with  either  Fn,  Lam
(Sigma), or galectin-1 for 16 h at 4 °C. Additionally, Fn- and
Lam-coated wells were initially incubated with 0.2 or 2 µg/
cm2 galectin-1 before the cells were plated. Fn and Lam were
solubilized in 1× PBS (pH 7.4) to yield a final density of 2 µg/
cm2. The plates were air dried, washed with 1× PBS and
preincubated with 1% BSA/PBS for one hour before plating
the cells. Trypsinized RPE cells were washed once in DMEM
with 10% FCS to quench trypsin activity. Suspensions of
2×104 cells were initially incubated in the presence or absence
of  galectin-1  concentrations,  ranging  0–250  µg/ml,  or
100  mM  β-lactose  (the  hapten  to  block  carbohydrate-
dependent binding of galectin-1) for 30 min at 37 °C and 5%
CO2. Cells were then added to the wells and allowed to attach
for 1 h at 37 °C and 5% CO2.
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carefully  washed  plates  two  times  with  PBS  using  an
automated  plate  washer  (Molecular  Devices,  Ismaning,
Germany). The extent of adherence was measured by MTT
assay, as described for cell viability testing. The number of
attached living cells was proportional to the absorbance of
Formazan at 550 nm, as determined by a scanning multiwell
spectrophotometer (Molecular Devices). Experiments were
performed in triplicate and repeated at least three times.
Cell  migration  assay:  Migration  was  assayed  by  a
modification  of  the  Boyden  chamber  method,  using
microchemotaxis chambers (Neuro Probe, Gaithersburg, MD)
and polycarbonate filters (Nucleopore, Karlsruhe, Germany)
with a pore size of 8.0 µm [42]. Before filters were placed
between the chambers, they were either left uncoated, or they
were coated with either Fn, Lam, galectin-1, or mixtures of
glycoprotein and galectin-1 to yield a final density of 2 µg/
cm2 of each substratum. DMEM containing 20 ng/ml platelet
derived growth factor-BB (PDGF-BB, PeproTech, London,
UK) was placed in the lower chamber [43], and 5×104 cells,
which  had  been  previously  incubated  with  different
concentrations of galectin-1 or β-lactose, as described for cell
adhesion, were placed into the upper chamber. The chamber
was incubated at 37 °C and 5% CO2 for 5 h. The filters were
then removed, and the RPE cells on the upper side of the filter
were scraped off with a cotton-tipped swab. RPE cells that
migrated to the lower side of the filter were fixed in situ in
methanol  and  stained  with  hematoxylin.  Five  randomly
chosen  fields  were  examined  for  cell  density  at  200×
magnification  with  a  phase-contrast  microscope  (Leica).
Experiments were performed in duplicate and repeated at least
four times.
Cell spreading assay: Cell spreading was assayed on four
chamber uncoated slides or on slides coated with either Fn,
Lam, or galectin-1 to yield a final concentration of 2 µg/cm2.
Alternatively,  Fn-  and  Lam-coated  wells  were  initially
incubated with 0.2 or 2 µg/cm2 galectin-1 before the cells were
plated. RPE cells were cultured as described in the human RPE
cell culture section. Cells were isolated by trypsinization,
which involved 0.25% trypsin in 5 mM EDTA, washed once
in DMEM with 10% FCS and twice with medium containing
0.4% FCS, then plated at a concentration of 5×104 cells per
well and allowed to spread for 3.5 h at 37 °C and 5% CO2
[42,44]. Cells were washed three times in PBS, fixed with
methanol, stained with Giemsa, and mounted in Kaiser gelatin
(Merck). To quantify cell spreading, we photographed four
separate fields using phase contrast microscopy. The spread
cells showed a clearly defined halo of cytoplasm around the
nucleus and were counted. Each experiment was performed
in duplicate wells and was repeated at least three times.
Statistical analysis: Statistical analysis was performed using
SPSS 14 software (SPSS Inc., Chicago, IL). The Student-t-
test for independent samples with a confidence interval of
95% was used to calculate statistically significant differences
between  samples.  A  p≤0.05  was  considered  statistically
significant.
RESULTS
Galectin-1 alters RPE cell morphology and binds the cell
surface:  To  determine  whether  galectin-1  is  capable  of
triggering cellular responses, we added purified protein to
RPE  cell  suspensions  before  plating  them.  Cells  were
observed  by  phase-contrast  microscopy.  Regular  cell
spreading with intercellular spaces was invariably seen in
untreated controls 90 min after plating (Figure 1A). In the
galectin-1-treated cells, however, both the morphology and
the cell density were markedly different (Figure 1B). Cell
spreading was less frequent, with a predominance of rounded
cells or loose cell clusters, which suggested that adhesion
between cells was stronger than adhesion between cells and
the substratum. This may in part arise from the cross-linking
activity of the homodimeric lectin, which–when able to bind
cells–has  the  capacity  to  agglutinate  cells.  To  pinpoint
carbohydrate-dependent binding as relevant, we included the
inhibitor, β-lactose, in the assay panel. Its presence in the
medium  had  no  effect  on  cell  morphology  (Figure  1D).
However, when galectin-1 was added in the presence of β-
lactose to block its cell binding, agglutination and rounding
of cells was restored (Figure 1C).
As a next step, biotinylated galectin-1 was added to assess
the binding pattern of galectin-1 at the level of the individual
cell.  Immunocytochemical  monitoring  of  cultured  human
RPE cells clearly revealed pronounced staining of the cell
membranes,  suggesting  cell-surface  binding  of  the  lectin
(Figure 1E-H). To exclude cytotoxic effects of this binding,
MTT assays were performed to confirm cell viability.
Lack of in vitro toxicity of RPE-bound galectin-1: In cells
treated with galectin-1 for 24 h, MTT conversion rates reached
110%  to  127%  of  the  untreated  control,  indicating  that
survival was not affected by the presence of galectin-1 (Figure
2A). After 48 h exposure to galectin-1, the MTT conversion
rate by RPE cells decreased by about 15% (Figure 2B). The
observed reduction in cell number after 48 h may most notably
be due to an antiproliferative effect of galectin-1, as indicated
by [methyl-3H]thymidine uptake (data not shown).
Effect of galectin-1 on RPE cell adhesion: To test whether
galectin-1 has an influence on RPE cell attachment to the
ECM glycoproteins, Fn and Lam, we performed quantitative
adhesion  assays  with  untreated  cells  and  with  RPE  cells
preincubated  with  different  concentrations  of  galectin-1
before they were plated. Galectin-1 pretreatment significantly
decreased  attachment  to  both  glycoproteins  in  a  dose-
dependent manner. Pretreatment of RPE cells with 12.5 µg/
ml galectin-1 resulted in a 26.4% (±2.9 SD) reduction in
attachment to Fn, whereas 250 µg/ml galectin-1 inhibited
attachment of more than 70% of treated RPE cells (Figure 3A).
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recognition domain, we performed control experiments in the
presence of 100 mM β-lactose. The presence of β-lactose
abolished  the  inhibition  of  RPE  attachment  caused  by
Figure 1. Effects of galectin-1 on the morphology of cultured human
retinal pigment epithelial cells and cell surface binding of galectin-1.
A-D: Human retinal pigment epithelial (RPE) cell suspensions were
preincubated for 35 min without galectin-1 (A), or with 125 μg/ml
galectin-1 (B), or 100 mM β-lactose before addition of 125 µg/ml
galectin-1 (C), or 100 mM β-lactose (D) in the medium. RPE cells
were then plated at a density of 0.5×104 cells per well in 96-well
plates and allowed to adhere for 90 min (A-D). The cells were
observed by light microscopy (magnification 100×). E-H: Galectin-1
is  detected  on  the  surface  of  human  RPE  cells  by
immunofluorescence. Cells were cultured on glass coverslips for 16
h before being treated with biotinylated galectin-1 (E). They were
fixed, then stained with a fluorescent streptavidin conjugate. For
controls (G), untreated cells were exposed to streptavidin conjugate
alone. Nuclei were counterstained with 1 µg/ml Hoechst 33342 (F,
H). Localization of bound galectin-1 was visualized by fluorescence
microscopy at a 400x magnification. The bar represents 100 μm.
galectin-1.  Clearly,  attachment  was  dependent  on
carbohydrate binding (Figure 3B).
Comparable effects of galectin-1 on RPE cell attachment
were observed for Lam-coated wells, where 72.8% (±11.4 SD;
p<0.05) of RPE cells were unable to attach following initial
incubation  with  250  µg/ml  galectin-1  (Figure  3C).  As
observed for attachment on Fn, this effect was completely
eliminated in the presence of β-lactose (Figure 3D). These
findings indicate that the inhibitory effect of galectin-1 on
RPE attachment to both matrix glycoproteins is mediated via
its lectin site.
To  determine  whether  binding  of  galectin-1  to  Fn  is
involved in the observed effect, we initially incubated 150 µg/
ml soluble Fn with galectin-1 for 30 min before adding it to
suspended RPE cells. In parallel experiments, RPE cells were
Figure 2. RPE cell viability was unaffected by galectin-1. Human
RPE cells were seeded in 96-well plates at an initial density of
1×104 cells/well in DMEM supplemented with 10% FCS. Cells were
cultured overnight before the indicated concentrations of galectin-1
were added to the medium in DMEM containing 2% FCS, and cell
survival was assessed by MTT assay after 24 h (A) and 48 h (B) of
culture. RPE cells cultured with incubation medium alone served as
controls. The values were normalized to untreated controls (100%)
and  represent  the  mean±SD  of  six  experiments  performed  in
duplicate wells.
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2166initially  incubated  with  soluble  Fn  alone,  followed  by
incubation  with  125  µg/ml  galectin-1.  Alternatively,  cells
were either left untreated (control) or treated with soluble Fn
alone or with 125 µg/ml galectin-1 alone. Saturation of RPE
cells with Fn alone had no effect on RPE attachment when
compared to untreated control cells. However, preincubation
with  soluble  Fn,  followed  by  addition  of  galectin-1,  or
addition of Fn that had been initially incubated with galectin-1
resulted in an inhibitory effect on RPE attachment that was
equivalent  to  that  induced  by  galectin-1  alone  (data  not
shown). The inhibitory effect of galectin-1 on RPE attachment
may most likely arise from cell surface-binding of galectin-1,
Figure 3. Effect of galectin-1 on RPE cell adhesion. A, C: Galectin-1
inhibits RPE cell attachment to Fn (A) and Lam (C) in a dose-
dependent manner. RPE suspensions were incubated for 35 min with
the indicated concentrations of galectin-1 (Gal-1) and then plated on
wells coated with Fn or Lam at a density of 2×104 cells per well.
Values  indicate  means±SD  of  four  experiments  performed  in
triplicate  and  are  expressed  as  percentage  of  controls  without
galectin-1 in the medium. B, D: The inhibitory effect of galectin-1
on attachment of RPE cells to Fn (B) and Lam (D) is mediated via
carbohydrate  binding.  RPE  cells  were  initially  incubated  in  the
presence or absence of 100 mM β-lactose (lac) as indicated. Values
represent means±SD of three experiments performed in triplicate and
are expressed as percentage of controls (Co) without galectin-1 or
β-lactose in the medium. Statistical analysis was performed using
Students t-test and a p value <0.05 was considered as statistically
significant (*).
rather than from binding to or saturating Fn. This possibility
would be in agreement with the immunocytochemical data.
Furthermore, the presence of an excess of Fn or binding of
galectin-1 to Fn does not interfere with the inhibitory effects
of galectin-1.
As  part  of  delineating  whether  galectin-1  itself  is  a
substratum for RPE cell attachment, we coated 96-well plates
with 2 µg/cm2 of either galectin-1, Fn, or Lam, or a mixture
of galectin-1 and glycoprotein. The overall attachment rate of
RPE cells was higher on Fn- than on Lam-coated wells (Figure
4). In terms of numbers of attached cells per well, galectin-1,
Lam, and uncoated plastic were equally attractive for RPE
cells, suggesting that Lam does not promote, but also does not
inhibit, attachment of RPE cells to tissue culture plastic. Fn
markedly increased RPE cell adhesion to levels 231% higher
than in the control uncoated wells. This increase was reduced
by 44% and 80% when the Fn-coated wells had additionally
been precoated with 0.2 µg/cm2 and 2 µg/cm2 galectin-1,
respectively  (Figure  4A).  The  combination  of  Lam  with
galectin-1 had no further influence on RPE attachment, which
was equal to uncoated wells. These findings indicate that
galectin-1 is not an adhesion substrate for RPE cells, and that
it can even reduce the adhesive properties of Fn.
Effect of galectin-1 on RPE cell migration: To analyze the
effect of added galectin-1 on RPE cell migration, we coated
Boyden chamber membranes with either Fn or Lam. RPE cell
suspensions were incubated in the presence or absence of
different concentrations of galectin-1 before being placed into
the  upper  chamber.  To  ensure  an  efficient  directional
migration, we added PDGF-BB to the lower chamber as a
chemotactic agent. Pretreatment of RPE cells with different
concentrations  of  galectin-1  caused  a  dose-dependent
decrease of RPE cell migration in both cases (Figure 5A,B).
At  the  highest  concentration  studied,  galectin-1  inhibited
migration by more than 90%.
Next, we studied the effect of galectin-1 as a substratum
on PDGF-stimulated RPE cell migration. For this purpose,
Boyden chamber membranes were precoated with 2 µg/cm2
of glycoprotein or galectin-1 or mixtures thereof. Overall,
RPE migration on Fn and Lam was equal to migration on
uncoated filters (Figure 5C), being slightly increased on Fn
(116.0% ±5.6 SD) and slightly decreased on Lam (85.6%±3.8
SD). On membranes coated with galectin-1 alone, migration
of RPE cells was reduced to 30.2% (±9.1 SD; p<0.05) of that
seen for uncoated controls. To delineate whether saturation
with  galectin-1  affected  RPE  migration  on  Fn  or  Lam,
membranes  precoated  with  Fn  or  Lam  were  treated  with
galectin-1. Migration was reduced by a further 57% for Fn
(Figure 5C). No inhibitory effect was seen for Lam. These
observations correspond well with the findings for RPE cell
attachment, inferring that galectin-1 does not stimulate RPE
migration and can even attenuate migration on Fn. A hallmark
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2167of RPE in PVR is their extensive spreading, which prompted
Figure  4.  Galectin-1  as  substratum  does  not  support  RPE  cell
attachment. RPE cells were seeded on 96-well plates precoated with
Fn, or Fn+ Gal-1 (A), or Lam, or Lam+Gal-1 (B), or Gal-1 alone
(A, B; see Methods section). Controls (Co) were plated on protein-
free  plastic.  Values  represent  means±SD  of  three  experiments
performed in triplicate and are expressed as percentage of controls
plated on uncoated plastic.
study of galectin-1 in this respect.
Figure  5.  Soluble  galectin-1  reduces  RPE  cell  migration  on
fibronectin and laminin in a dose-dependent manner. A, B: Boyden
chamber membranes were coated with either fibronectin (Fn; A) or
laminin (Lam; B). RPE suspensions were incubated for 35 min with
the indicated concentrations of galectin-1 and then 5×104 cells were
placed into the upper chamber. After five hours at 37 °C, cells that
migrated into the lower surface of the filter were fixed, stained and
quantified.  Values  indicate  means±SD  of  four  experiments
performed in duplicate and are expressed as percentage of controls
without galectin-1 in the medium. C: Galectin-1 as a substratum does
not support RPE cell migration. Boyden chamber membranes were
coated with either Fn alone, Fn+galectin-1 (Gal-1), Lam alone, Lam
+Gal-1, or Gal-1 alone. RPE cells were then placed into the upper
chamber at a density of 5×104 cells per chamber and allowed to
migrate as described above. Values indicate means±SD of three
experiments performed in duplicate and are expressed as percentage
of controls (Co). Statistical analysis was performed using Students
t-test and a p value <0.05 was considered as statistically significant
(*). RPE cells migrating on uncoated filters served as controls (Co).
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2168Effect of galectin-1 on RPE cell spreading and morphology:
The influence of added galectin-1 on spreading of RPE cells
was measured on four chamber slides coated with either Fn or
Lam. RPE cell suspensions were pretreated with different
concentrations of galectin-1 before plating. After 3.5 h of
incubation,  regular  cell  spreading  with  establishment  of
cytoplasmic protrusions, perinuclear halos, and intercellular
spaces  was  invariably  seen  in  untreated  controls  (Figure
6A,C).  In  the  galectin-1-treated  cells,  however,  both
morphology and density of the cells were drastically changed.
At all concentrations studied, cell spreading was less frequent,
being replaced by a predominance of rounded cells lacking
cytoplasmic  protrusions  or  by  loose  cell  clusters  (Figure
6B,D). Quantitative assessment revealed an inhibition of RPE
cell spreading in 86.9% (±1.4 SD; p<0.05) of the cells on Fn
and 90.9% (±1.2 SD; p<0.05) on Lam, when cells had been
incubated with 250 µg/ml galectin-1 before plating (Figure 7).
Finally, to analyze whether galectin-1 as a substratum had
an impact on RPE cell spreading, four chamber slides were
coated with the same substrates as described for migration and
attachment experiments. When compared to Fn and Lam,
spreading on galectin-1 alone was severely impaired, with
about 50% of cells showing a lack of cytoplasmic protrusions
and halo formation (Figure 6E, Figure 7C,). In combination
with Fn and Lam, galectin-1 had essentially no inhibitory
effect on RPE spreading (Figure 7C) and failed to modify cell
morphology (Figure 6F,G).
DISCUSSION
Attachment of cells to the retinal surface, spreading along the
surface, and migration with subsequent formation of cellular
membranes [7,42] are the initial events in the cellular cascade
that leads to PVR. In this study, we found that galectin-1 added
to the medium of cultured RPE cells is an effective inhibitor
of many of the processes involved in these early events of PVR
pathogenesis.  With  no  visible  toxicity  or  effects  on  RPE
viability, the lectin inhibited RPE attachment, spreading, and
migration  at  concentrations  less  than  62.5  µg/ml.  The
galectin-1-mediated effects were dependent on the binding of
β-galactosides, as ascertained by haptenic inhibition by β-
lactose. As a substratum, galectin-1 impaired spreading and
migration of RPE cells and profoundly reduced attachment to
and migration on Fn. As previously demonstrated [45], we
confirmed a clear substratum preference of RPE cells to Fn
over Lam. Since Fn is a main component of the provisional
ECM in early PVR, galectin-1-mediated inhibition of RPE
attachment  and  migration  on  Fn,  both  when  added
exogenously and as a component of the ECM, underscores the
potential of galectin-1 to modify the behavior of RPE cells on
this important substratum.
When localized extracellularly, galectins are active in
modulating cell-cell and cell-matrix interactions in a positive
or  negative  manner,  depending  on  the  biologic  and
physiologic context, as has been shown experimentally for
various types of human tumor cells [30]. Relevant bridging
ligands include the poly-N-acetyllactosamine chains present
on  Lam,  Fn,  or  integrins  and  branched  glycans  in
glycoproteins or glycolipids [22,46,47]. In the present study,
galectin-1 added to the medium in the dose range studied
caused  a  marked  reduction  in  adhesion,  spreading,  and
migration  levels  of  cultured  RPE  cells,  accompanied  by
rounding and agglutination of the cells.
In  view  of  the  cell-surface  binding  of  galectin-1,  as
determined by biotinylated galectin-1, it is possible that this
lectin can exert its inhibitory activities on RPE behavior by
blocking  access  of  physiologic  ligands  to  cell  surface
Figure 6. Morphology of cells used for collection of data in Figure
7. Representative light microscopic fields are shown. (A) Untreated
RPE cells grown on Fn; (B) after preincubation with 250 μg/ml Gal-1
on  Fn;  (C)  Untreated  RPE  cells  grown  on  Lam;  (D)  after
preincubation with 250 ug/ml Gal-1 on Lam; (E) Untreated RPE cells
grown on Gal-1; (F) on Gal-1 and Fn; (G) on Gal-1 and Lam.
Spreading  cells  (S)  were  defined  as  cells  with  cytoplasmic
protrusions and perinuclear halo formation, and non spreading cells
(NS)  as  rounded  cells  with  little  cytoplasmic  spreading.  The
photographs represent a 100 fold magnification.
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2169receptors.  This  would  have  the  effect  of  disrupting  focal
Figure 7. Galectin-1 inhibits spreading of RPE cells on fibronectin
and laminin. A, B: RPE suspensions were incubated for 35 min with
the indicated concentrations of galectin-1 and then plated on four
chamber slides coated with either Fn (A) or Lam (B) at a density of
5×104 cells per chamber. Cells were allowed to spread in DMEM for
3.5 h at 37 °C before fixation and Giemsa staining. Values indicate
means±SD  of  four  experiments  performed  in  duplicate  and  are
expressed  as  percentage  of  controls  without  galectin-1  in  the
medium. (C) RPE cell spreading on galectin-1 as a substrate. Four
chamber slides were coated with either Fn alone, Fn+galectin-1
(Gal-1), Lam alone, Lam+Gal-1, or Gal-1 alone. RPE cells were then
plated at a density of 5×104 cells per chamber and allowed to spread.
Results were obtained from evaluation of four separate fields by
examining at least 100 cells per field. Values indicate means±SD of
three  experiments  performed  in  duplicate  and  are  expressed  as
percentage of cells spreading on Fn or Lam as a substrate. Statistical
analysis was performed using Students t-test and a p value <0.05 was
considered as statistically significant (*).
adhesions,  which  could  then  result  in  the  observed
morphological alterations. For example, in carcinoma cells,
relevant glycoprotein ligands of galectin-1 were identified as
lamp-1  and  lamp-2,  carcinoembryonic  antigen,  and  the
fibronectin  receptor  [33,48-50].  In  skeletal  myocytes  and
human smooth muscle cells, galectin-1 interacts with α7β1
and α1β1 integrins, respectively [24,51]. Of note, β1-integrin
plays an important role in RPE adhesion and migration on Fn
and Lam. It has been shown in other cell types that galectin-1
modulates adhesive properties of cells by interacting with β1
integrins  [24],  thus  modifying  their  ability  to  adhere  to
components of the ECM such as Lam and Fn [24,52,53].
Although the nature of the galectin-1 counter-receptors
on the RPE cell surface is not yet known, it is likely that
galectin-1 might be involved in the modulation of cell-matrix
interactions. The result would be a decrease in the adhesive
and  motile  properties  of  dedifferentiated  RPE  cells  via
interaction with functional glycans on the cell surface. This
notion is further underscored by the finding that RPE cell
behavior was sensitive to the presence or absence of galectin-1
on the culture substratum. When exposed to surface-presented
Fn and galectin-1, the level of attachment and migration was
markedly reduced when compared to Fn as a substrate alone.
This again raises the possibility that galectin-1 may compete
with Fn for ligands, or may block its access on the cell surface.
In  contrast,  none  of  the  activities  tested  was  sensitive  to
galectin-1 as a substratum bound to Lam, most likely because
Lam, per se, reportedly has only weak affinity for RPE cells
[42,45].
As noted previously, a salient aspect of galectin-1 activity
is its specificity in a given cell type. In agreement with our
findings, galectin-1 can decrease migration in different cell
types including colon cancer cells [54], smooth muscle cells,
and  eosinophils  [24,55].  In  contrast,  in  astrocytic  tumors,
galectin-1 increases cell migration [56], and has recently been
reported to increase adhesion, proliferation and migration, in
combination  with  vascular  endothelial  growth  factor,  in
human  umbilical  vein  endothelial  cells,  as  a  result  of
neuropilin-1 binding [57]. Comparable cell type-dependent
functional divergence has been reported for cell attachment:
galectin-1 can stimulate tumor cell attachment to Lam and Fn
[26,30,31], but adhesion and spreading of skeletal myoblasts
and vascular smooth muscle cells on Lam is inhibited [24].
Clearly, it will now be essential to provide insights into the
molecular  and  regulatory  mechanisms  involved  in  the
inhibitory effects of galectin-1 on RPE behavior.
In their review, Gabius et al. [58] noted galectins may
interact with various types of (glyco)protein, depending on
their cellular location. In a previous study, we found reduced
RPE migration on Lam after silencing galectin-1 expression
by siRNA transfection [37]. At first sight, these results may
appear  conflicting.  However,  reduced  overall  galectin-1
transcription  will  likely  have  ramifications  on  gene
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2170expression,  which  could  account  for  the  observed  effect.
Stable inhibition of galectin-1 expression in a glioblastoma
cell line diminished the expression of several genes that either
directly or indirectly influence adhesion and motility [59].
Only recently, Kleinman et al. [60] revealed that, irrespective
of its target, siRNA binds to cell-surface toll-like receptor-3
(TLR-3) on RPE cells and triggers TLR-3 signaling, thus
altering RPE function independent of any RNA-interference
effect. This raises the possibility that the TLR-3-mediated
siRNA-class  effect  may  have  accounted  for  the  observed
reduced  migratory  activity  following  galectin-1  siRNA
transfection. However, this contribution may have been only
partial, since scrambled siRNA did not significantly reduce
RPE migration.
In summary, our results indicate that galectin-1 is able to
inhibit early cellular events in PVR pathogenesis–namely,
attachment, migration, and spreading of RPE cells–in a dose-
dependent  manner  and  at  nontoxic  concentrations.  When
looking at lectins, it should be noted that working with an
endogenous protein will likely exclude the immunogenicity
encountered with plant proteins, such as the mushroom lectin
aforementioned. At any rate, it is wise to view these in vitro
data  with  adequate  caution.  During  PVR  or  vitreoretinal
surgery [61], serum (glyco)proteins containing a considerable
number  of  potential  glycan  ligands  may  attenuate  the
inhibitory effect of added galectin-1 on RPE cell behavior;
thus,  increased  lectin  concentrations  may  be  required.  In
addition, a panel of ECM proteins beyond Fn and Lam has
been found in PVR but has not yet been studied. Furthermore,
ligands for galectin-1 are present in the interphotoreceptor
matrix [62,63] or on endothelial cells [57,64]. Therefore, for
a future in vivo application, possible deleterious effects of
intravitreally administered galectin-1 on neighboring tissues
certainly will have to be excluded.
Nevertheless, we have shown that an endogenous lectin,
produced  by  human  RPE  cells,  can  profoundly  and
differentially affect the behavior of RPE cells in contact with
major ECM components present in PVR. Given the combined
effect  of  galectin-1  on  RPE  attachment,  migration,  and
spreading,  and  its  dose-dependent  titratability  on  RPE
behavior,  this  lectin  deserves  further  investigation  as  a
possible novel agent for the management of PVR or other
anomalous wound-healing disorders.
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